Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Triaziquone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR known ✓ | P02766 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 2/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.31 |
| ▸ | TDP2 | O95551 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triaziquone SCHEMBL887253 | 0.98 | MAPT (0.39) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL10720448 | 0.90 | TP53 (0.34) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL1546343 | 0.88 | MAPT (0.41) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL8974524 | 0.86 | MAPT (0.42) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL11350903 | 0.86 | HTT (0.42) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL9865090 | 0.86 | TP53 (0.36) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL2063810 | 0.86 | MAPT (0.44) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL7117809 | 0.86 | MAPT (0.44) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL6387848 | 0.85 | MAPT (0.41) | TP53MAPTSTAT3HTTSMN1; SMN2 | |
| Triaziquone SCHEMBL1157120 | 0.84 | MAPT (0.36) | TP53MAPTSTAT3HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 205 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023116891-A1 | STROMAL MATERIAL FOR ENCAPSULATING CELLS, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 北京瑞健高科生物科技有限公司 | 2023-06-29 | — | — | WO | claimed |
| US-7816527-B2 | Quinazoline-containing kits for labeling aldehyde or ketone moieties | Life Technologies Corporation (US) | 2010-10-19 | — | — | US | claimed |
| US-20260098251-A1 | METHODS FOR NUCLEIC ACID EXTRACTION FROM TISSUES | WATERS TECHNOLOGIES CORPORATION (US) | 2026-04-09 | — | — | US | disclosed |
| WO-2024188173-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE COMPRISING SAME, AND USE THEREOF | 苏州瑞博生物技术股份有限公司 | 2024-09-19 | — | — | WO | disclosed |
| US-20240074440-A1 | METHODS OF USE OF SEED-ORIGIN ENDOPHYTE POPULATIONS | INDIGO AG, INC. | 2024-03-07 | — | — | US | disclosed |
| CN-117298275-A | Method for treating hematological malignancies and ewing's sarcoma | 库拉肿瘤学公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11819027-B2 | Streptomyces endophyte compositions and methods for improved agronomic traits in plants | INDIGO AG, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-112204020-B | Dioxetane compounds and their use for detecting microorganisms | 尼米斯技术公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11793202-B2 | Methods of use of seed-origin endophyte populations | INDIGO AG, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-11788040-B2 | Diagnostic device and related method | EMPE DIAGNOSTICS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| CN-110691779-B | Method for treating hematological malignancies and ewing's sarcoma | 库拉肿瘤学公司 | 2023-10-10 | — | — | CN | disclosed |
| EP-0147430-A1 | METHOD AND COMPOSITION FOR DETERMINATION OF GAMMA GLUTAMYL TRANSPEPTIDASE | COULTER ELECTRONICS INC. (US) | 1985-07-10 | — | — | EP | disclosed |
| US-4514509-A | Method for the diagnosis of Legionnaires' disease | INDIANA UNIVERSITY FOUNDATION (US) | 1985-04-30 | — | — | US | disclosed |
| US-4505818-A | HYDROXYAMINATED SULFONATED STYRENE-DIVINYLBENZENE COPOLYMERS | HITACHI CHEMICAL CO., LTD. (JP) | 1985-03-19 | — | — | US | disclosed |
| WO-1984004931-A1 | METHOD AND COMPOSITION FOR DETERMINATION OF GAMMA GLUTAMYL TRANSPEPTIDASE | COULTER ELECTRONICS (US) | 1984-12-20 | — | — | WO | disclosed |
| US-4438030-A | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-03-20 | — | — | US | disclosed |
| EP-0101655-A2 | Production of herpes simplex viral proteins | AMERICAN CYANAMID COMPANY (US) | 1984-02-29 | — | — | EP | disclosed |
| US-4341761-A | Antibodies to immunogenic peptides and their use to purify human fibroblast interferon | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-07-27 | — | — | US | disclosed |
| US-4311639-A | Immunogenic interferon peptides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1982-01-19 | — | — | US | disclosed |
| US-4254021-A | Tissue specific protein and process for preparing same | BEHRINGWERKE AKTIENGESELLSCHAFT (DE) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098251-A1 | METHODS FOR NUCLEIC ACID EXTRACTION FROM TISSUES | MMP13, DNASE1, MMP1 | TTR 1635/4885TP53 4021/4885MAPT 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.